IBIO, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2022-01-26 09:17:12 ET IBIO

Item 7.01. Regulation FD Disclosure.

On January 25, 2022, iBio, Inc. (the "Company") issued a press release announcing that is it moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid ("N") protein and plans to file an IND application before the end of calendar 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01. Other Events

On January 25, 2022, the Company issued a press release announcing that is it moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid ("N") protein and plans to file an IND application before the end of calendar 2022.

Item 9.01. Financial Statements and Exhibits.